文献速递核素与放射性配体治疗

改善靶向放射性核素治疗的联合策略

Combination Strategies to Improve Targeted Radionuclide Therapy.
PubMed 文献 · J Nucl Med · 2020-10-09

本文综述了靶向放射性核素治疗(TRT)的联合策略,包括与化疗及放射增敏剂联用,旨在提高疗效、降低剂量与毒性;部分临床试验显示获益,另有试验未观察到明确生存获益。

要点

  • TRT已获批用于神经内分泌肿瘤、神经母细胞瘤和非霍奇金淋巴瘤。
  • 联合策略包括同步化疗及PARP、mTOR抑制剂等放射增敏剂。
  • 部分联合治疗试验结果积极,部分未显示明确生存获益。

核心结论

  • TRT联合其他治疗策略具有提高疗效、降低剂量与毒性的潜力,但临床证据尚不一致。

研究设计与样本

  • 本文为综述,汇总了文献中报道的TRT联合策略并评估其治疗潜力。

主要发现

  • 已获批的TRT药物包括177Lu-DOTATATE、131I-MIBG、Bexxar和Zevalin。
  • 现有临床证据表明仅小部分患者达到完全缓解。
  • 部分联合治疗临床试验显示积极结果,另一些未显示明确生存获益。

局限性

  • 部分联合治疗的临床试验缺乏公开的临床前证据支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In recent years, targeted radionuclide therapy (TRT) has emerged as a promising strategy for cancer treatment. In contrast to conventional radiotherapy, TRT delivers ionizing radiation to tumors in a targeted manner, reducing the dose that healthy tissues are exposed to. Existing TRT strategies include the use of 177Lu-DOTATATE, 131I-metaiodobenzylguanidine, Bexxar, and Zevalin, clinically approved agents for the treatment of neuroendocrine tumors, neuroblastoma, and non-Hodgkin lymphoma, respectively. Although promising results have been obtained with these agents, clinical evidence acquired to date suggests that only a small percentage of patients achieves complete response. Consequently, there have been attempts to improve TRT outcomes through combinations with other therapeutic agents; such strategies include administering concurrent TRT and chemotherapy, and the use of TRT with known or putative radiosensitizers such as poly(adenosine diphosphate ribose) polymerase and mammalian-target-of-rapamycin inhibitors. In addition to potentially achieving greater therapeutic effects than the respective monotherapies, these strategies may lead to lower dosages or numbers of cycles required and, in turn, reduce unwanted toxicities. As of now, several clinical trials have been conducted to assess the benefits of TRT-based combination therapies, sometimes despite limited preclinical evidence being available in the public domain to support their use. Although some clinical trials have yielded promising results, others have shown no clear survival benefit from particular combination treatments. Here, we present a comprehensive review of combination strategies with TRT reported in the literature to date and evaluate their therapeutic potential.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Chan TG, O'Neill E, Habjan C, et al. Combination Strategies to Improve Targeted Radionuclide Therapy. J Nucl Med. 2020. PMID: 33037092. doi:10.2967/jnumed.120.248062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。